News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Kazia Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX Small Caps Lunch Wrap: Who else is going to be checking for monsters under the bed tonight?
Health & Biotech
ASX Health Stocks: Kazia says goodbye to the ASX; IMEXHS wins $2m contract in Colombia
News
Top 10 at 11: Lithium and gold are popular again, but Kazia’s de-listing and falling fast
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Local markets end 0.4pc higher led by big banks and a few small biotechs
News
ASX Health Stocks: Proteomics soars 13pc after US sets reimbursement price for PromarkerD
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks up as Avita Medical gets US FDA green light
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech
ASX Health Stocks: Osteopore licenses its bone regeneration technology; Kazia resolves problem with Nasdaq
Health & Biotech
After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023
News
CLOSING BELL: The ASX engine rooms roar to life, delivering a +1.2% touch worthy of Midas himself
Health & Biotech
Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half
Health & Biotech
ASX Health Stocks: Kazia gets published in renowned Journal, Cochlear rejects ACCC’s claims
News
ASX Quarterlies: Fintechs stand out as Biotechs press forward with clinical trials
Health & Biotech
Kazia Therapeutics lays groundwork for a possible launch in the US
Health & Biotech
Kazia says diversification is the key to drug development
Health & Biotech
